NASDAQ:KRRO Korro Bio Q3 2024 Earnings Report $10.64 -0.89 (-7.72%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$10.88 +0.24 (+2.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Korro Bio EPS ResultsActual EPS-$2.26Consensus EPS -$2.55Beat/MissBeat by +$0.29One Year Ago EPSN/AKorro Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKorro Bio Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time4:00PM ETUpcoming EarningsKorro Bio's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Korro Bio Earnings HeadlinesKorro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 | globenewswire.comKorro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm HoldingJune 15, 2026 | seekingalpha.comUniversal Basic Income ALREADY existsRobert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal basic income. His Patriot Income Plan - funded by 14 partnerships controlling America's critical oil and gas infrastructure - already pays 10% a year with 42 payouts annually. Some investors are already collecting $4,800 a month. One has built income up to $25,000 a month. These partnerships have averaged 20% annual gains since 2020, with no U.S. tax dollars involved. The next payout drops in days.July 26 at 1:00 AM | Freedom Financial (Ad)Korro Bio Stockholders Approve Directors, Pay and AuditorJune 11, 2026 | tipranks.comOne Korro Bio Insider Raised Stake By 19% In Previous YearJune 11, 2026 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)May 30, 2026 | theglobeandmail.comSee More Korro Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email. Email Address About Korro BioKorro Bio (NASDAQ:KRRO) is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases. The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics. Lead candidate KB103 is an investigational enzyme replacement therapy designed to address congenital hyperbilirubinemia by restoring deficient UGT1A1 activity. In parallel, Korro Bio is advancing a portfolio of live microbial drug candidates aimed at modulating the human microbiome to treat unmet medical needs in gastroenterology and oncology. These programs reflect the company’s dual focus on systemic enzyme therapies and targeted microbial approaches. Founded in 2019 and headquartered in Boston, Massachusetts, Korro Bio completed its initial public offering on the Nasdaq under the ticker KRRO in late 2021. The company collaborates with leading academic and industry partners to expand its enzyme discovery platform and accelerate translational research. Led by an experienced management team with backgrounds in biotherapeutics, protein science and drug development, Korro Bio serves a global pharmaceutical customer base and is committed to advancing innovative treatments from bench to bedside.View Korro Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyRTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?Broadcom May Be the Biggest Winner From Alphabet's EarningsDefense Earnings Show Readiness Now and Modernization Ahead Upcoming Earnings Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
